These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20040278)

  • 1. Frontiers in platelet inhibition.
    Varon D; Shai E; Spectre G
    Discov Med; 2009 Dec; 8(43):242-6. PubMed ID: 20040278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet agents.
    Varon D; Spectre G
    Hematology Am Soc Hematol Educ Program; 2009; ():267-72. PubMed ID: 20008209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel resistance?
    Gurbel PA; Tantry US
    Thromb Res; 2007; 120(3):311-21. PubMed ID: 17109936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet P2 receptors: old and new targets for antithrombotic drugs.
    Cattaneo M
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADP-receptor blockade: A case for personalised pharmacotherapy?
    Zürn CS; Geisler T; Gawaz M
    Thromb Haemost; 2010 Mar; 103(3):496-506. PubMed ID: 20076845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New antiplatelet agents.
    Spectre G; Varon D
    Curr Opin Hematol; 2009 Sep; 16(5):365-70. PubMed ID: 19587588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
    Anderson SD; Shah NK; Yim J; Epstein BJ
    Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
    Angiolillo DJ; Suryadevara S; Capranzano P; Zenni MZ; Guzman LA; Bass TA
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):1-14. PubMed ID: 19089929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group.
    Second Chinese Cardiac Study (CCS-2) Collaborative Group
    J Cardiovasc Risk; 2000 Dec; 7(6):435-41. PubMed ID: 11189013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy.
    Ben-Dor I; Kleiman NS; Lev E
    Am J Cardiol; 2009 Jul; 104(2):227-33. PubMed ID: 19576352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease.
    Koo MH; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2008; 16(6):314-8. PubMed ID: 18923235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.
    Bauriedel G; Skowasch D; Schneider M; Andrié R; Jabs A; Lüderitz B
    Am Heart J; 2003 Feb; 145(2):343-8. PubMed ID: 12595854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.